idarubicin has been researched along with oligonucleotides in 5 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (20.00) | 29.6817 |
| 2010's | 4 (80.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Altman, JK; Andreeff, M; Borthakur, G; Brandwein, J; Carter, BZ; Estey, EH; Hedley, DW; Jacob, C; Jolivet, J; Karp, JE; Kassis, J; LaCasse, E; Mak, DH; Morris, SJ; Schiller, GJ; Schimmer, AD; Tallman, MS; Xu, W | 1 |
| Andreeff, M; Borthakur, G; Byrd, AL; Carter, BZ; Estey, E; Kantarjian, H; Konopleva, M; Mak, DH; Morris, SJ | 1 |
| Baer, MR; Ball, ED; Borthakur, G; Cortes, J; Dipersio, J; Fernandez, HF; Goodman, M; Kantarjian, H; Kolitz, JE; Wetzler, M | 1 |
| Andre, V; Andreeff, M; Brandt, JT; Callies, S; Erba, HP; Juckett, M; Kadam, S; Lahn, M; Sayar, H; Schmidt, S; Van Bockstaele, D | 1 |
| Giovinazzo, H; Nelson, WG; Walker, D; Wyhs, N; Yegnasubramanian, S | 1 |
4 trial(s) available for idarubicin and oligonucleotides
| Article | Year |
|---|---|
Phase I/II trial of AEG35156 X-linked inhibitor of apoptosis protein antisense oligonucleotide combined with idarubicin and cytarabine in patients with relapsed or primary refractory acute myeloid leukemia.
Topics: Acute Disease; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Female; Gene Expression Regulation, Neoplastic; Humans; Idarubicin; Leukemia, Myeloid; Male; Middle Aged; Oligonucleotides; Peripheral Nervous System Diseases; Recurrence; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Treatment Outcome; X-Linked Inhibitor of Apoptosis Protein | 2009 |
XIAP antisense oligonucleotide (AEG35156) achieves target knockdown and induces apoptosis preferentially in CD34+38- cells in a phase 1/2 study of patients with relapsed/refractory AML.
Topics: Aged; Antigens, CD; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Caspases; Cytarabine; Drug Administration Schedule; Drug Dosage Calculations; Female; Gene Expression; Humans; Idarubicin; Leukemia, Myeloid, Acute; Male; Middle Aged; Myeloid Progenitor Cells; Oligonucleotides; Recurrence; RNA, Messenger; X-Linked Inhibitor of Apoptosis Protein | 2011 |
Phase 2 randomized study of p53 antisense oligonucleotide (cenersen) plus idarubicin with or without cytarabine in refractory and relapsed acute myeloid leukemia.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Female; Genes, p53; Humans; Idarubicin; Leukemia, Myeloid, Acute; Male; Middle Aged; Oligonucleotides; Oligonucleotides, Antisense; Recurrence; Treatment Failure | 2012 |
Safety and pharmacokinetics of the antisense oligonucleotide (ASO) LY2181308 as a single-agent or in combination with idarubicin and cytarabine in patients with refractory or relapsed acute myeloid leukemia (AML).
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Demography; Female; Humans; Idarubicin; Inhibitor of Apoptosis Proteins; Leukemia, Myeloid, Acute; Male; Middle Aged; Oligonucleotides; Oligonucleotides, Antisense; Recurrence; Survivin; Treatment Outcome | 2013 |
1 other study(ies) available for idarubicin and oligonucleotides
| Article | Year |
|---|---|
Time-Resolved Fluorescence Resonance Energy Transfer Assay for Discovery of Small-Molecule Inhibitors of Methyl-CpG Binding Domain Protein 2.
Topics: Aurintricarboxylic Acid; Benzenesulfonates; DNA; DNA Methylation; DNA-Binding Proteins; Dose-Response Relationship, Drug; Drug Discovery; Drug Evaluation, Preclinical; Fluorescence Resonance Energy Transfer; Fluorescent Dyes; High-Throughput Screening Assays; Humans; Idarubicin; Mitoxantrone; Oligonucleotides; Protein Binding; Sp1 Transcription Factor | 2014 |